Monoclonal antibody
A monoclonal antibody (mAb) is an antibody preparation derived from a single B-cell clone or engineered to recognize one defined antigenic determinant with high specificity.
A monoclonal antibody (mAb) is an antibody preparation derived from a single B-cell clone or engineered to recognize one defined antigenic determinant with high specificity. Most therapeutic monoclonal antibodies are based on immunoglobulin G (IgG) molecules and contain antigen-binding Fab regions and an Fc region that can interact with immune effector systems. Their selectivity enables blockade of soluble mediators or receptors, neutralization of toxins and viruses, depletion or activation of defined cell populations, and delivery of cytotoxic agents through antibody–drug conjugates.
Monoclonal antibodies are used in oncology, autoimmune and inflammatory disease, infectious disease, transplantation, and diagnostic medicine. Their mechanisms may include ligand or receptor neutralization, inhibition of Signaling pathways, immune-cell recruitment, complement activation, or alteration of receptor-mediated cell survival. Antibody specificity is also exploited in immunohistochemistry and other laboratory assays. Therapeutic formats include fully human, humanized, Fc-modified, Fc-silent, bispecific, multispecific, and antibody-fragment products. Examples of their application include targeting tumor-associated antigens such as B7-H3, blocking inflammatory cytokines, and neutralizing pathogens such as SARS-CoV-2; nirsevimab is an example of a monoclonal antibody developed for prevention of viral infection. Manufacturing and quality control must address attributes such as affinity, aggregation, glycosylation, stability, biological activity, and immunogenicity.
- 5C psychological antecedents of vaccine hesitancy toward maternal RSV vaccines and infant monoclonal antibodies among pregnant and postpartum women and their partners in China: A multicenter, dyadic survey design, cross-sectional study. PMID 42714313
Where the papers sit
17 papers study monoclonal antibody directly. Those 17 do not group into themes. Work ranges from vaccine hesitancy and allergen neutralization to ADC therapy, antibody design, nanoparticle biodistribution and formulation stability. The topics share antibody-related methods or products but no common biological question or research direction. They are no more alike than papers drawn from anywhere in the corpus. 1 new direction follows.
A monoclonal antibody can function as an antibiotic-resistance antidote rather than as a direct disease-targeting therapeutic
The OXA23-targeting monoclonal antibody C32 in carbapenem-resistant Acinetobacter baumannii departs from the set’s usual roles of blocking host cytokines or allergens, targeting tumor-associated antigens, or serving as a drug-delivery and bioconjugation platform. Instead, C32 neutralizes an extracellular bacterial β-lactamase at an epitope near its catalytic groove, thereby restoring carbapenem susceptibility and reducing meropenem MICs in a co-culture model. This makes the antibody an adjunct that rescues an existing antibiotic from pathogen-mediated inactivation, rather than the primary antimicrobial agent itself. 42376991Jun
Recent Findings on monoclonal antibody
Diverse Antibody Applications: Monoclonal antibodies are advancing through clinical testing, targeted neutralization, and delivery engineering across inflammatory, allergic, oncologic, and infectious diseases 42462749Jul42462750Jul42234540Jun42621997Aug42376991Jun. Secukinumab, duvakitug, and Stapokibart improved disease outcomes with generally acceptable safety, while SHR-A2102 showed activity in advanced solid tumours alongside hematologic toxicities consistent with its topoisomerase I inhibitor payload 42234540Jun42462749Jul42462750Jul42621997Aug42636836Aug. Dose and format influenced performance: higher-dose duvakitug produced larger response differences, total IgE remained unchanged during Stapokibart treatment, and Fab binding persisted longer than mAb potency after hydrogel release 42462749Jul42462750Jul42621997Aug42379548Jun. Molecular studies are expanding antibody function through low-data sequence design, α-Gal IgE blockade, OXA23 neutralization, DR3 inhibition, and SPATOC-mediated dual probe attachment, while B7-H3 targeting links antibodies with exosome biology and precision oncology 42665538Aug42677844Sep42376991Jun42364076Jun42619102Aug41964005Apr. Manufacturing and translation are moving toward mechanistic control, using FT-IR monitoring, water-content optimization, thermoresponsive hydrogels, and whole-body PBPK models, while vaccine hesitancy findings emphasize prenatal counseling for both parents 42429162Jul42504521Jul42379548Jun42527729Jul42714313Sep.
Written from 17 PubMed abstracts, each one cited by PMID above. Published: 2026-08-20. Last written: 2026-09-11 by GPT. Drafted by language models from published abstracts; not medical advice.